D. Ross Camidge, MD, PhD

Articles

Standard Treatments for NRG1 Fusion+ NSCLC

May 6th 2024

D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses standard treatments for patients with non–small cell lung cancer who harbor NRG1 fusions.

DESTINY-Lung04: First-Line Trastuzumab Deruxtecan in HER2-Mutated NSCLC

May 1st 2024

Edward S. Kim, MD, MBA, discusses the DESTINY-Lung04 trial, a study evaluating trastuzumab deruxtecan as first-line treatment for patients with HER2-mutated NSCLC.

The Role of Trastuzumab Deruxtecan in HER2-Mutated NSCLC

May 1st 2024

Experts on HER2-mutated NSCLC discuss the patient populations in which they’d utilize trastuzumab deruxtecan and share their clinical experiences with the therapy.

Differences Between DNA and RNA Testing for NRG1

April 29th 2024

D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses differences between DNA and RNA fusions for detecting NRG1 fusions.

Prevalence of NRG1 Fusions in Lung Cancer

April 29th 2024

D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses the prevalence of NRG1 fusions in lung cancer.

Camidge and Su Compare Lung Cancer Treatment Strategies in China and the United States

April 25th 2024

Drs Camidge and Su discuss the aspects of medicine that strengthened Dr Su’s interest in oncology and the details of delivering lung cancer care in China.

DESTINY-Lung01 & DESTINY-Lung02: T-DXd in Metastatic HER2-Mutated NSCLC

April 24th 2024

Lyudmila A. Bazhenova, MD, and D. Ross Camidge, MD, PhD, review the DESTINY-Lung01 and DESTINY-Lung02 trials, and the panel provides its impressions of the data.

Role of ADCs in HER2-Mutated NSCLC

April 24th 2024

The panel discusses the role of antibody-drug conjugates (ADCs) and the treatment of patients with HER2-mutated non–small cell lung cancer.

Biomarker Testing Challenges in HER2-mutated NSCLC

April 17th 2024

Experts on HER2-mutated non–small cell lung cancer provide clinical insights on biomarker testing challenges and the role of reflex testing.

Diagnosing HER2-mutated NSCLC

April 17th 2024

A panel of thoracic oncologists introduce themselves and discuss biomarker testing strategies and the diagnosis of HER2-mutated non–small cell lung cancer (NSCLC).

Camidge and Rimel on the Importance of Cultivating Inclusive Gynecologic Oncology Practices

April 15th 2024

Drs Camidge and Rimel spotlight Dr Rimel’s career journey and the work she does to expand medical care for transgender patients.

Camidge and Rabinowitz Reflect on Finding Strength and Inspiration on Both Sides of a Cancer Diagnosis

April 4th 2024

Drs Camidge and Rabinowitz discuss the balance between professional and personal life that Rabinowitz navigated when he was diagnosed with lung cancer.

Camidge and Lewis Discuss the Perspective of Being Both a Patient and Physician

March 14th 2024

Drs Camidge and Lewis discuss how Dr Lewis’ MEN-1 diagnosis has affected his professional life and the importance of seeking patient perspectives.

Dr Camidge on the Rationale for the TRUST-II Trial in ROS1+ NSCLC

September 20th 2023

D. Ross Camidge, MD, PhD, discusses the rationale for the ongoing phase 2 TRUST-II trial of taletrectinib in patients with non–small cell lung cancer harboring ROS1 mutations.

Dr. Camidge Discusses Treatment of Patients With ALK+ NSCLC

January 24th 2019

D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses optimal treatment strategies for patients with ALK-mutated non–small cell lung cancer.

Dr. Camidge on Mechanisms of Resistance to TKIs in NSCLC

November 27th 2018

D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses mechanisms of resistance to targeted therapies in oncogene-driven non–small cell lung cancer.

Dr. Camidge on Optimal Therapy in EGFR+ NSCLC

November 10th 2018

D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses optimal treatment regimens for patients with EGFR-positive non–small cell lung cancer.

Dr. Camidge on the FDA Approval of Pembrolizumab for Squamous NSCLC

October 31st 2018

D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses the FDA approval of first-line pembrolizumab (Keytruda) in metastatic squamous non–small cell lung cancer regardless of PD-L1 expression.

Dr. Camidge on the KEYNOTE-024 Trial in NSCLC

August 23rd 2018

D. Ross Camidge, MD, PhD, professor, Division of Medical Oncology, Joyce Zeff Chair in Lung Cancer Research, School of Medicine, Division of Medical Oncology, University of Colorado, discusses implications of the KEYNOTE-024 trial in non–small cell lung cancer (NSCLC).

Dr. Camidge Discusses Unmet Needs in ALK+ Lung Cancer

November 1st 2017

D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses unmet needs for patients with ALK-positive lung cancer.